Relationship of β-catenin and postchemotherapy histopathologic changes with overall survival in patients with hepatoblastoma

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 8, 2012, Pages

  Gupta, Kirti ^a   Rane, Swapnil ^a   Das, Ashim ^a   Marwaha, Ram Kumar ^a   Menon, Prema ^a   Rao, K L N ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

catenin; hepatoblastoma; postchemotherapy changes

Indexed keywords

BETA CATENIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; MITOSIS INDEX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; CELL DIFFERENTIATION; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MITOTIC INDEX; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; WNT SIGNALING PATHWAY;

EID: 84868667716     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182580471     Document Type: Article

References (32)

1. Raney B. Hepatoblastoma in children: A review. J Pediatr Hematol Oncol. 1997;19:418-422.
2. Armengol C, Cairo S, Fabre M, et al. Wnt signaling and hepatocarcinogenesis: The hepatoblastoma model. Int J Biochem Cell Biol. 2011;43:265-270.
3. Park WS, Oh RR, Park JY, et al. Nuclear localization of betacatenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483-490.
4. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999;59:269-273.
5. Schnater JM, Kohler SE, LamersWH, et al. Where do we stand with hepatoblastoma? A review. Cancer. 2003;98:668-678.
6. Rowland JM. Hepatoblastoma: Assessment of criteria for histologic classification. Med Pediatr Oncol. 2002;39:478-483.
7. Stocker J, Conran R, Selby D. Tumor and pseudotumors of the liver. In: Stocker J, Askin F, eds. Pathology of Solid Tumors in Children. London: Chapman and Hall; 1998:83-110.
8. Udatsu Y, Kusafuka T, Kuroda S, et al. High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int. 2001;17:508-512.
9. Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/b-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130-1134.
10. Munemitsu S, Albert I, Souza B, et al. Regulation of intracellular b-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA. 1995;92:3046-3050.
11. Inomata M, Ochiai A, Akimoto S, et al. Alteration of b-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res. 1996;56:2213-2217.
12. He TC, Sparks AB, Rago C, et al. Identification c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512.
13. Ishak KG, Glunz PK. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Cancer. 1967;20:396-422.
14. Kasai M, Watanabe I. Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. Cancer. 1970;25:552-563.
15. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, et al. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. 1997;74:593-599.
16. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine and fluorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study. J Clin Oncol. 1993;11:96-99.
17. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Pediatric Oncology (SIOP) Study SIOPEL-1. Eur J Cancer. 2000;36:1418-1425.
18. Vos A. Primary liver tumors in children. Eur J Surg Cancer. 1995;21:101-105.
19. Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated b-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155: 703-710.
20. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24: 245-250.
21. Seeling JM, Miller JR, Gil R, et al. Regulation of b-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283:2089-2091.
22. Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancers. Science. 1998;282: 284-287.
23. Roose J, Huls G, van Beest M, et al. Synergy between tumor suppressor APC and the b-catenin-Tcf4 target Tcf1. Science. 1999;285:1923-1926.
24. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol. 2009;218:86-94.
25. von Schweinitz D, Schmidt D, Fuchs J, et al. Extramedullary hematopoiesis and intratumoral production of cytokines in childhood hepatoblastoma. Pediatr Res. 1995;38:555-563.
26. Saxena R, Leake JL, Shafford EA, et al. Chemotherapy effects on hepatoblastoma. A histological study. Am J Surg Pathol. 1993;17:1266-1271.
27. Lowichik A, Zhou H, Pysher TJ, et al. Therapy associated changes in childhood tumors. Adv Anat Pathol. 2000;7: 341-359.
28. Heifetz SA, French M, Correa M, et al. Hepatoblastoma: The Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. Pediatr Pathol Lab Med. 1997;17:857-874.
29. Wang LL, Filippi RZ, Zurakowski D, et al. Effects of neoadjuvant chemotherapy on hepatoblastoma: A morphologic and immunohistochemical study. Am J Surg Pathol. 2010;34: 287-299.
30. Coffin CM, Rulon J, Smith L, et al. Pathologic features of rhabdomyosarcoma before and after treatment: A clinicopathologic and immunohistochemical analysis. Mod Pathol. 1997;10:1175-1187.
31. Zuppan CW, Beckwith JB, Weeks DA, et al. The effect of preoperative therapy on the histologic features of Wilms' tumor. An analysis of cases from the Third National Wilms' Tumor Study. Cancer. 1991;68:385-394.
32. Ló pez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. 2009;40:783-794.